SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-128783
Filing Date
2023-05-01
Accepted
2023-05-01 08:01:11
Documents
16
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d411815d10ka.htm   iXBRL 10-K/A 619882
2 EX-31.3 d411815dex313.htm EX-31.3 4209
3 EX-31.4 d411815dex314.htm EX-31.4 4161
  Complete submission text file 0001193125-23-128783.txt   879901

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cadl-20221231.xsd EX-101.SCH 4971
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cadl-20221231_cal.xml EX-101.CAL 671
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cadl-20221231_def.xml EX-101.DEF 1676
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20221231_lab.xml EX-101.LAB 21944
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20221231_pre.xml EX-101.PRE 17105
10 EXTRACTED XBRL INSTANCE DOCUMENT d411815d10ka_htm.xml XML 8355
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40629 | Film No.: 23870094
SIC: 2836 Biological Products, (No Diagnostic Substances)